BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Extra | May 15, 2019
Company News

ImmunoGen looks to next Phase III after FDA rebuffs accelerated approval path for mirvetuximab

ImmunoGen plans to start a second Phase III trial before year end of mirvetuximab soravtansine that will focus on ovarian cancer patients with high FOLR1 expression after FDA told the company that data from a...
BC Week In Review | Mar 8, 2019
Clinical News

ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen lost $2.21 (47%) to $2.51 on March 1 after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant ovarian...
BC Extra | Mar 1, 2019
Clinical News

ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen Inc. (NASDAQ:IMGN) lost $2.21 (47%) to $2.51 on Friday after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
BC Innovations | Dec 11, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest combinations of bispecific small molecules targeting fluorescein and CAIX, PSMA or FOLR1 plus anti-fluorescein CAR T cells could help treat triple-negative breast cancer (TNBC). The bispecific adapter molecules consist...
Items per page:
1 - 7 of 7